Addex Research Highlights mGlu7 Modulation for Sleep & Wakefulness

Addex Therapeutics announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands evidence supporting mGlu7 as a promising therapeutic target for central nervous system disorders, including mood disorders, anxiety, and PTSD. The study showed ADX71743 increased wakefulness and reduced both REM and non-REM sleep in rats, while also altering stress-induced changes in key neurotransmitters.